Overall, these findings demonstrate the applicability of the sample-specific biological-rPSL workflow with DIA to investigate differentially expressed, lower-abundance cancer-associated proteins in response to treatment and capturing key IFN-γ response gene signatures in an in vitro setting. The gene discussed is IFNG; the disease is cancer.